RITA Medical Systems to Provide Educational Grant to Support Continuing Medical Education ProgramMOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--June 3, 2004--

Continuing Medical Education Program on Medscape Internet Site to Inform Medical Oncologists and Interventional Radiologists about Radiofrequency Ablation Treatment for Soft Tissue Cancer Tumors

    RITA Medical Systems, Inc. (Nasdaq:RITA) today announced the
Company will provide to Medscape an unrestricted educational grant to
support a live online continuing medical education program (CME). This
CME program will educate medical oncologists and interventional
radiologists about the use of radiofrequency ablation (RFA) treatment
for soft tissue cancer tumors. The program will be archived for one
year on Medscape's web site and will also be available to patients as
an information source for cancer treatment options.
    Mr. Joseph DeVivo, President and CEO of RITA Medical Systems,
said, "We believe that an education program is the best way to inform
medical oncologists and interventional radiologists about the use of
radiofrequency ablation to treat cancerous and benign tumors."
    Scheduled faculty presenters for the education program include
Peter Mueller, M.D., Professor of Radiology, Harvard Medical School,
Director of Abdominal Imaging and Interventional Radiology,
Massachusetts General Hospital, and Lawrence S. Blaszkowsky, M.D.,
Instructor in Medicine, Harvard Medical School, Massachusetts General
Hospital Cancer Center.
    RITA Medical will make available information about the education
program during the upcoming American Society of Clinical Oncology
(ASCO) annual meeting, June 5th through the 8th, in New Orleans. The
CME program is scheduled to take place June 23, 2004, from 7:00 p.m.
to 8:00 p.m. Eastern Time. Physicians may register for the event at
www.medscape.com/cmelive/treatlivercancer.
    About RITA Medical Systems, Inc.

    RITA Medical Systems develops, manufactures and markets innovative
products for patients with solid cancerous or benign tumors.
    The statements in this news release related to the use of
educational programs to inform physicians about the use of RFA to
treat patients with cancerous or benign tumors, and the company's
expectations regarding the extension of its technology to applications
beyond the liver are forward-looking statements involving risks and
uncertainties that could cause actual results to differ materially
from those in such forward-looking statements. Information regarding
these risks is included in RITA Medical's filings with the Securities
and Exchange Commission.

CONTACT: RITA Medical Systems, Inc. Don Stewart/Stephen Pedroff, 650-314-3400 dstewart@ritamed.com spedroff@ritamed.com or Allen & Caron Inc. (investors) Jill Bertotti, 949-474-4300 jill@allencaron.com or SurfMedia Communications (media) Juliana Minsky, 805-962-3700 jm@surfmedia.com

SOURCE: RITA Medical Systems, Inc.